BRIGHT MINDS BIOSCIENCES INC (DRUG) competitors & alternatives
Health Care · NASDAQ
BRIGHT MINDS BIOSCIENCES INC (DRUG)'s top competitors and alternatives — its most similar public companies — include XENON PHARMACEUTICALS INC (XENE), MAPLIGHT THERAPEUTICS INC (MPLT), ATAIBECKLEY INC (ATAI), ALTO NEUROSCIENCE INC (ANRO), ANAVEX LIFE SCIENCES CORP (AVXL), RAPPORT THERAPEUTICS INC (RAPP), NUVECTIS PHARMA INC (NVCT), PACIRA BIOSCIENCES INC (PCRX), REZOLUTE INC (RZLT), GENERATE BIOMEDICINES INC (GENB), TYRA BIOSCIENCES INC (TYRA) and XOMA ROYALTY CORP (XOMA). These are BRIGHT MINDS BIOSCIENCES INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top DRUG competitors & alternatives
-
XENON PHARMACEUTICALS INCXENEHealth Care
A pre-commercial neuroscience biotech racing to bring azetukalner, a differentiated potassium channel opener, through Phase 3 trials for epilepsy and…
$66.18 (as of 2026-07-22) · market cap $6.7B
-
MAPLIGHT THERAPEUTICS INCMPLTHealth Care
MapLight Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel, targeted treatments for central nervous…
$35.31 (as of 2026-07-22) · market cap $1.6B
-
ATAIBECKLEY INCATAIHealth Care
A clinical-stage biotechnology company dedicated to developing innovative mental health therapies through a diverse pipeline of neuropsychiatric treatments.
$7.18 (as of 2026-07-22) · market cap $2.7B
-
ALTO NEUROSCIENCE INCANROHealth Care
Alto Neuroscience is a clinical-stage biotech developing precision medicines for neuropsychiatric conditions by using biomarkers to match patients to targeted…
$27.23 (as of 2026-07-22) · market cap $1.0B
-
ANAVEX LIFE SCIENCES CORPAVXLHealth Care
Anavex is a clinical-stage biotech developing sigma-1 receptor agonists for neurodegenerative and rare CNS disorders, with lead program ANAVEX 2-73 in multiple…
$2.55 (as of 2026-07-22) · market cap $234M
-
RAPPORT THERAPEUTICS INCRAPPHealth Care
Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex…
$41.33 (as of 2026-07-22) · market cap $2.1B
-
NUVECTIS PHARMA INCNVCTHealth Care
Nuvectis is an early-stage oncology biotech developing NXP900, a novel SRC/YES1 kinase inhibitor designed to overcome drug resistance in solid tumors including…
$19.29 (as of 2026-07-22) · market cap $608M
-
PACIRA BIOSCIENCES INCPCRXHealth Care
Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis…
$25.59 (as of 2026-07-22) · market cap $1.0B
-
REZOLUTE INCRZLTHealth Care
Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
$5.00 (as of 2026-07-22) · market cap $481M
-
GENERATE BIOMEDICINES INCGENBHealth Care
Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein…
$13.90 (as of 2026-07-22) · market cap $1.8B
-
TYRA BIOSCIENCES INCTYRAHealth Care
Tyra Biosciences is a clinical-stage biotech company developing precision small-molecule inhibitors to overcome drug resistance in cancer, particularly…
$30.59 (as of 2026-07-22) · market cap $1.8B
-
XOMA ROYALTY CORPXOMAHealth Care
A lean-infrastructure royalty aggregator that generates non-dilutive capital for biotech developers in exchange for long-duration milestone and royalty rights…
$40.17 (as of 2026-07-21) · market cap $710M
Not quite? Describe exactly what you want →
Peers are BRIGHT MINDS BIOSCIENCES INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: BRIGHT MINDS BIOSCIENCES INC (DRUG).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.